赛诺菲子公司Genzymy起诉Sarepta指控杜兴药物专利侵权

2024-08-01 03:06

Sanofi (NASDAQ:SNY)-owned Genzyme has sued Sarepta Therapeutics (NASDAQ:SRPT) accusing the latter's Duchenne muscular dystrophy therapy Elevidys of violating two of its patents.
The patents in question involve technology used to alter viruses so that they can be used as a delivery mechanism for gene therapy.
"John Fraser Wright and Guang Qu, the inventors of the subject matter claimed in the '542 Patent and the '721 Patent, discovered that the use of certain high ionic strength solutions for preparing and storing [recombinant adeno-associated virus] vectors can prevent significant aggregation of virus particles at the concentrations needed for effective gene therapy," the lawsuit reads. "They invented rAAV formulations and related methods in which vector particles remain soluble when elevated ionic strengths are used during purification and for final vector formulation."
Genzyme is asking for unspecified damages from the federal court in Delaware.
This is not the first time Elevidys (delandistrogene moxeparvovec) has faced patent litigation. The same court in January determined that a patent REGENXBIO (RGNX) and the University of Pennsylvania said Sarepta was infringing was invalid.

More on Sanofi, Sarepta Therapeutics